Leukemia & Lymphoma最新文献_第4页

MLLT10 rearranged acute leukemia-finding order in ambiguity-a case series from a North Indian tertiary care center. MLLT10在模棱两可的情况下重新排列了急性白血病的发现顺序-来自北印度三级保健中心的病例系列。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-01 Epub Date: 2026-08-26 DOI: 10.1080/10428194.2026.2719275

Shreyam Acharya, Richa Chauhan, Jasmita Dass, Vinu Balraam Kv, Ayush Agarwal, Ganesh Kv, Mukul Aggarwal, Pradeep Kumar, Rishi Dhawan, Tulika Seth, Manoranjan Mahapatra

引用次数: 0

Not just infection: when lymphoproliferation signals inborn errors of immunity. 不仅仅是感染：当淋巴细胞增生表明先天免疫缺陷时。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-01 Epub Date: 2026-09-02 DOI: 10.1080/10428194.2026.2722425

Lucy C Fox

引用次数: 0

Pre- and post-transplant serum albumin levels and outcomes after allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia. 成人急性髓性白血病移植前后血清白蛋白水平和同种异体造血细胞移植后的预后。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-01 Epub Date: 2026-07-06 DOI: 10.1080/10428194.2026.2695317

Corentin Orvain, Megan Othus, Mariia Byelykh, Gary Schoch, Chris Davis, Brenda M Sandmaier, Roland B Walter

{"title":"Pre- and post-transplant serum albumin levels and outcomes after allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia.","authors":"Corentin Orvain, Megan Othus, Mariia Byelykh, Gary Schoch, Chris Davis, Brenda M Sandmaier, Roland B Walter","doi":"10.1080/10428194.2026.2695317","DOIUrl":"10.1080/10428194.2026.2695317","url":null,"abstract":"Hypoalbuminemia has been repeatedly linked to increased non-relapse mortality (NRM) after allogeneic hematopoietic cell transplantation (HCT); a recent analysis also suggested an association with relapse risk. To evaluate the relationship between hypoalbuminemia, NRM, and relapse, we assessed its prognostic role in 1258 adults with MDS (myelodysplastic neoplasm)/AML or AML allografted while in remission between 2006 and 2023. After multivariable adjustment, low pre-HCT serum albumin levels were statistically significantly associated with NRM (hazard ratio [HR] = 0.67, p = 0.028), relapse-free survival (RFS; HR = 0.73, p = 0.005), and overall survival (OS; HR = 0.72, p = 0.007) but not relapse (HR = 0.77, p = 0.070). A day-28 landmark analysis showed day +28 hypoalbuminemia to be associated with NRM (HR = 0.31, p < 0.001), RFS (HR = 0.67, p < 0.001), and OS (HR = 0.52, p < 0.001) but not relapse (HR = 1.08, p = 0.6). Together, our data indicate that pre- and post-HCT serum albumin levels are independently associated with NRM and survival in AML patients undergoing allogeneic HCT.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"2253-2265"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148397026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting MCL-1 in cancer: promise, pitfalls, and the path forward. 靶向MCL-1治疗癌症：希望、陷阱和前进的道路。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-01 Epub Date: 2026-09-06 DOI: 10.1080/10428194.2026.2723846

Aloke Sarkar, Natalia Timofeeva, Varsha Gandhi

引用次数: 0

How to treat hepatic extra-medullary involvement of myeloma: a case report and review of literature. 如何治疗肝髓外浸润骨髓瘤：1例报告及文献复习。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-01 Epub Date: 2026-08-16 DOI: 10.1080/10428194.2026.2715203

Ece Vural, Hamit Aytekin, Emine Durak, Ramazan Ocal, Oral Nevruz, Işınsu Kuzu, Serdar Savaş Gül, Meral Beksac

{"title":"How to treat hepatic extra-medullary involvement of myeloma: a case report and review of literature.","authors":"Ece Vural, Hamit Aytekin, Emine Durak, Ramazan Ocal, Oral Nevruz, Işınsu Kuzu, Serdar Savaş Gül, Meral Beksac","doi":"10.1080/10428194.2026.2715203","DOIUrl":"10.1080/10428194.2026.2715203","url":null,"abstract":"Extramedullary hepatic involvement is particularly rare. Here, we summarize published reports of hepatic myeloma treatment achieving infrequent and short-lived responses. Approach to a newly diagnosed multiple myeloma patient who presented with diffuse intrahepatic infiltration and cholestasis under frontline quadruplet induction will be presented here to complement the review. Contrary to earlier reports, he achieved a rapid response in/outside or marrow with elranatamab monotherapy. Importantly, this response enabled subsequent high dose melphalan and autologous stem cell transplantation (ASCT), which, otherwise, would not have been feasible. Currently under the 11th month of elranatamab treatment, patient is still in measurable residual disease (MRD)(-) CR. To our knowledge there has been no cases or series achieving such deep and durable responses for hepatic EMD. Elranatamab can be an effective and safe drug for extensive cholestatic liver myeloma involvement. Our results are quite premature, necessitating additional reports confirming the efficacy and safety of anti-BCMA bispecifics.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"2327-2336"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148760276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dose optimization of single-agent inotuzumab ozogamicin in adults with relapsed/refractory acute lymphoblastic leukemia. 单药inotuzumab ozogamicin治疗复发/难治性急性淋巴细胞白血病成人的剂量优化

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-01 Epub Date: 2026-08-18 DOI: 10.1080/10428194.2026.2714343

Daniel J DeAngelo, Ying Chen, Ryan D Cassaday, Jennifer E Hibma, Derek Z Yang, May Garrett, Fan Zhang, Svetoslav H Dimitrov, Erik R Vandendries, Hagop M Kantarjian

引用次数: 0

Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study. Venetoclax和低甲基化药物与其他疗法的对比：一项国际、多中心、回顾性队列研究综述。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-01 Epub Date: 2026-07-29 DOI: 10.1080/10428194.2026.2696455

Jacqueline S Garcia, Pinkal Desai, Joshua F Zeidner, Ofir Wolach, Thomas W LeBlanc, Sameem Abedin, Pankit Vachhani, Kendra Sweet, Yakir Moshe, Daniel A Pollyea, Catherine Lai, David Levitz, Boaz Nachmias, Lee Mozessohn, Marin Xavier, Tsila Zuckerman, Marina Konopleva, Evan C Chen, Maximilian Stahl, Yanqing Xu, Cat N Bui, Kaylee Miu, Xenia Schmidt, Moshe Grunspan, Chia-Wei Lin, Esprit Ma, Melissa Montez, Annie Guérin, Rebecca Burne, Kaitlyn Easson, Mohira Levesque-Leroux, Eugene Baraka, Aaron D Goldberg

{"title":"Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study.","authors":"Jacqueline S Garcia, Pinkal Desai, Joshua F Zeidner, Ofir Wolach, Thomas W LeBlanc, Sameem Abedin, Pankit Vachhani, Kendra Sweet, Yakir Moshe, Daniel A Pollyea, Catherine Lai, David Levitz, Boaz Nachmias, Lee Mozessohn, Marin Xavier, Tsila Zuckerman, Marina Konopleva, Evan C Chen, Maximilian Stahl, Yanqing Xu, Cat N Bui, Kaylee Miu, Xenia Schmidt, Moshe Grunspan, Chia-Wei Lin, Esprit Ma, Melissa Montez, Annie Guérin, Rebecca Burne, Kaitlyn Easson, Mohira Levesque-Leroux, Eugene Baraka, Aaron D Goldberg","doi":"10.1080/10428194.2026.2696455","DOIUrl":"10.1080/10428194.2026.2696455","url":null,"abstract":"Venetoclax (VEN) plus hypomethylating agents (HMA) is approved for newly diagnosed (ND) acute myeloid leukemia (AML) in patients ineligible for intensive chemotherapy (IC). This international retrospective chart review involving 17 academic sites included 576 adults with ND AML treated with VEN+HMA and matched controls who received non-VEN regimens (11/2019-08/2024). VEN+HMA patients were matched 1:1 to controls by age and European LeukemiaNet 2017 risk. Of 288 VEN+HMA patients, 192 were IC-ineligible (≥75 years or ≥1 comorbidity). Compared to controls receiving high- or low-intensity regimens, IC-ineligible VEN+HMA patients had significantly higher composite complete remission rates (63.7% vs. 46.0%; p < 0.01) and numerically higher median overall survival (17.4 [95% CI: 13.3-21.0] vs. 13.6 [95% CI: 10.5-15.9] months) and transfusion independence rates (63.7% vs. 53.2%). Similar trends were observed in subgroups aged ≥75 and ≥80 years. These findings reinforce the clinical effectiveness of VEN+HMA as a frontline regimen for IC-ineligible patients with AML.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"2282-2294"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148620390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort. 双特异性抗体和CAR-T细胞治疗复发或难治性多发性骨髓瘤的现实世界分析：全球TriNetX发现和当代验证队列

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-01 Epub Date: 2026-07-28 DOI: 10.1080/10428194.2026.2699285

Theo Leitner, Lorenz Oelschläger, Francisco Henriquez Mosquera, Christoph Schaefers, Lisa Leypoldt, Katja Weisel, Nikolas von Bubnoff, Markus Rückert, Christoph Kimmich, Helal Ahmed, Jan Vorwerk, Cyrus Khandanpour

{"title":"Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort.","authors":"Theo Leitner, Lorenz Oelschläger, Francisco Henriquez Mosquera, Christoph Schaefers, Lisa Leypoldt, Katja Weisel, Nikolas von Bubnoff, Markus Rückert, Christoph Kimmich, Helal Ahmed, Jan Vorwerk, Cyrus Khandanpour","doi":"10.1080/10428194.2026.2699285","DOIUrl":"10.1080/10428194.2026.2699285","url":null,"abstract":"Bispecific antibodies (BsAbs) and BCMA-directed CAR-T cell therapies have transformed late-line relapsed/refractory multiple myeloma (RRMM), yet real-world comparisons are confounded by treatment selection, line of therapy, and supportive care. We combined a global propensity-matched TriNetX discovery analysis with a contemporary, treatment-line-aware validation cohort. In TriNetX, 223,703 myeloma patients were identified up to 8 April 2026, matching yielded 822 BsAb- and 822 CAR-T-treated patients. BsAbs therapy showed inferior overall survival versus CAR-T (HR 2.015, 95% CI 1.592-2.551; p < 0.001), with similar signals in several biochemical risk subgroups. Cilta-cel outperformed ide-cel, whereas teclistamab and talquetamab were comparable. In the validation cohort (187 patients, 211 exposures), CAR-T therapy was used earlier and in fitter patients. After accounting for exposure and later-line disease, class-level OS and TTNT differences attenuated, while cilta-cel remained numerically favorable. Overall, treatment selection should be individualized rather than class-preferential.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"2295-2304"},"PeriodicalIF":2.1,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148604780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expanding access to leukemia specialists in the venetoclax era. 在venetoclax时代扩大白血病专家的机会。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-01 Epub Date: 2026-09-13 DOI: 10.1080/10428194.2026.2731270

Michael Daunov

引用次数: 0

Successful treatment using pemigatinib in a myeloid/lymphoid neoplasm with eosinophilia with FGFR1 rearrangement and rare chromosomal abnormalities. 使用pemigatinib成功治疗嗜酸性粒细胞增多伴FGFR1重排和罕见染色体异常的髓系/淋巴肿瘤。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-09-01 Epub Date: 2026-08-23 DOI: 10.1080/10428194.2026.2721772

Masaya Abe, Fumiaki Konishi, Yuki Nakagawa, Kyotaro Ohno, Kumiko Yoshikawa, Nobuhiro Shimizu, Yasuharu Sato, Ichiro Takata, Toru Ueki, Hiroyuki Sugiura

引用次数: 0